Free Cash Flow: A measure of financial performance calculated as operating cash flow minus capital expenditures. Calculated as: Cash Flow from Operations + Net Property, Plant & Equipment Exp (a negative number)
BridgeBio Oncology Therapeutics, Inc (BBOT) had Free Cash Flow of $-80.35M for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
-- |
|
$-56.45M |
|
-- |
|
-- |
|
$60.19M |
|
$-60.19M |
|
$3.73M |
|
$-56.45M |
|
$-56.45M |
|
$-56.45M |
|
$-56.45M |
|
$-56.45M |
|
$-56.45M |
|
$-60.19M |
|
$-60.00M |
|
80.05M |
|
80.05M |
|
$-705.20 |
|
$-705.20 |
|
| Balance Sheet Financials | |
$242.38M |
|
$0.88M |
|
$134.33M |
|
$376.71M |
|
$51.63M |
|
-- |
|
$1.96M |
|
$53.59M |
|
$323.11M |
|
$323.11M |
|
$323.11M |
|
80.11M |
|
| Cash Flow Statement Financials | |
$-80.28M |
|
$-239.68M |
|
$0.33M |
|
$373.82M |
|
$54.20M |
|
$-319.62M |
|
$11.10M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
4.69 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
|
Free Cash Flow |
$-80.35M |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-17.47% |
|
-17.47% |
|
-14.99% |
|
-17.47% |
|
$4.03 |
|
$-1.00 |
|
$-1.00 |
|